Literature DB >> 11278738

Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells.

M Wong1, S Uddin, B Majchrzak, T Huynh, A E Proudfoot, L C Platanias, E N Fish.   

Abstract

The chemokine RANTES (regulated on activation normal T cell expressed and secreted) and its cognate receptor CC chemokine receptor 5 (CCR5) have been implicated in regulating immune cell function. Previously we reported that in T cells, RANTES activation of CCR5 results in Stat1 and Stat3 phosphorylation-activation, leading to Stat1:1 and Stat1:3 dimers that exhibit DNA binding activity and the transcriptional induction of a Stat-inducible gene, c-fos. Given that RANTES and CCR5 have been implicated in T cell activation, we have studied RANTES-induced signaling events in a CCR5-expressing T cell line, PM1. RANTES treatment of PM1 T cells results in the rapid phosphorylation-activation of CCR5, Jak2, and Jak3. RANTES-inducible Jak phosphorylation is insensitive to pertussis toxin inhibition, indicating that RANTES-CCR5-mediated tyrosine phosphorylation events are not coupled directly to Galpha(i) protein-mediated events. In addition to Jaks, several other proteins are rapidly phosphorylated on tyrosine residues in a RANTES-dependent manner, including the Src kinase p56(lck), which associates with Jak3. Additionally our data confirm that the amino-terminally modified RANTES proteins, aminooxypentane-RANTES and Met-RANTES, are agonists for CCR5 and induce early tyrosine phosphorylation events that are indistinguishable from those inducible by RANTES with similar kinetics. Our data also demonstrate that RANTES activates the p38 mitogen-activated protein (MAP) kinase pathway. This is evidenced by the rapid RANTES-dependent phosphorylation and activation of p38 MAP kinase as well as the activation of the downstream effector of p38, MAP kinase-activated protein (MAPKAP) kinase-2. Pharmacological inhibition of RANTES-dependent p38 MAP kinase activation blocks MAPKAP kinase-2 activity. Thus, activation of Jak kinases and p38 MAP kinase by RANTES regulates the engagement of multiple signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278738     DOI: 10.1074/jbc.M010750200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

Review 1.  Chemokine receptors and neural function.

Authors:  Charlene Cho; Richard J Miller
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

2.  Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth.

Authors:  Thanh U Barbie; Gabriela Alexe; Amir R Aref; Shunqiang Li; Zehua Zhu; Xiuli Zhang; Yu Imamura; Tran C Thai; Ying Huang; Michaela Bowden; John Herndon; Travis J Cohoon; Timothy Fleming; Pablo Tamayo; Jill P Mesirov; Shuji Ogino; Kwok-Kin Wong; Matthew J Ellis; William C Hahn; David A Barbie; William E Gillanders
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

3.  Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replication.

Authors:  Ramtin Rahbar; Thomas T Murooka; Anna A Hinek; Carole L Galligan; Antonella Sassano; Celeste Yu; Kishore Srivastava; Leonidas C Platanias; Eleanor N Fish
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages.

Authors:  Brian Tomkowicz; Chuhee Lee; Vipa Ravyn; Ricky Cheung; Andrzej Ptasznik; Ronald G Collman
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

Review 5.  Chemokines and chemokine receptors: update on utility and challenges for the clinician.

Authors:  Ishan Roy; Douglas B Evans; Michael B Dwinell
Journal:  Surgery       Date:  2014-02-08       Impact factor: 3.982

6.  Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.

Authors:  Xiaoli Wang; Wei Zhang; Takefumi Ishii; Selcuk Sozer; Jiapeng Wang; Mingjiang Xu; Ronald Hoffman
Journal:  Cancer Res       Date:  2009-09-14       Impact factor: 12.701

7.  Targeting Autocrine CCL5-CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity.

Authors:  Yi Ban; Junhua Mai; Xin Li; Marisa Mitchell-Flack; Tuo Zhang; Lixing Zhang; Lotfi Chouchane; Mauro Ferrari; Haifa Shen; Xiaojing Ma
Journal:  Cancer Res       Date:  2017-04-17       Impact factor: 12.701

Review 8.  Is the CCR5 Δ 32 mutation associated with immune system-related diseases?

Authors:  Khodayar Ghorban; Maryam Dadmanesh; Gholamhossein Hassanshahi; Mohammad Momeni; Mohammad Zare-Bidaki; Mohammad Kazemi Arababadi; Derek Kennedy
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

9.  Intravenous tolerance modulates macrophage classical activation and antigen presentation in experimental autoimmune encephalomyelitis.

Authors:  Hongmei Li; Bogoljub Ciric; Jingxian Yang; Hui Xu; Denise C Fitzgerald; Mohamed Elbehi; Zoe Fonseca-Kelly; Shuo Yu; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  J Neuroimmunol       Date:  2009-02-01       Impact factor: 3.478

10.  Jak3 is involved in dendritic cell maturation and CCR7-dependent migration.

Authors:  Ana Rivas-Caicedo; Gloria Soldevila; Teresa I Fortoul; Andrés Castell-Rodríguez; Leopoldo Flores-Romo; Eduardo A García-Zepeda
Journal:  PLoS One       Date:  2009-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.